



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Description

This cell line has been engineered for use with the CRISPR Synergistic Activation Mediator (SAM) system to induce transcriptional activation and expression of any gene of interest. Cells stably express a mutated dCas9 (Streptococcus pyogenes CRISPR associated protein 9), lacking any endonuclease activity, fused to transcriptional activator VP64. Stable dCas9-VP64 expression is maintained with Blasticidin resistance. Cells also stably express P65 (Transcription Factor p65, or Nuclear Factor NF-κB p65) and HSF1 (Heat Shock Factor 1) fused with an MS2 tag, which is maintained with Hygromycin resistance. When these cells are transfected with an MS2- tagged sgRNA targeting the promoter region of the gene of interest, dCas9-VP64 and MS2-P65-HSF1 are recruited to the genomic DNA and begin transcription, inducing expression of the desired gene.

Application

1. Quickly generating CRISPR-activated cell pools or cell lines in HeLa cells
2. Implementing sgRNA CRISPRa screens in HeLa cells

Materials Provided

Components	Format
2 vials of frozen cells	Each vial contains 2×10^6 cells in 1 ml of 10% DMSO

Mycoplasma Testing

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.

Materials Required but Not Supplied

These materials are not supplied with this cell line but are necessary for cell culture and cellular assays. BPS Bioscience reagents systems are validated and optimized for use with this cell line and are highly recommended for best results. Media components are provided in the Media Formulations section.

Materials Required for Cell Culture

Name	Ordering Information
Thaw Medium 1	BPS Bioscience #60187
Growth Medium 1S	BPS Bioscience #78221

Storage Conditions

Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.

License Disclosure

Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide

For all questions, please email support@bpsbioscience.com.

Media Formulations

For best results, it is *highly recommended* to use these validated and optimized media from BPS Bioscience. To formulate a comparable but not BPS validated media, formulation components can be found below.



Note: Thaw Media does *not* contain selective antibiotics. However, Growth Media *does* contain selective antibiotics, which are used for maintaining cell lines over many passages. Cells should be grown at 37°C with 5% CO₂

Media Required for Cell Culture

Thaw Medium 1 (BPS Bioscience # 60187):

MEM medium (Thermo Fisher, #11095098) supplemented with 10% FBS (Thermo Fisher, #26140079) 1% non-essential amino acids (Corning, #25-025-CI), 1 mM Na pyruvate (Corning, #25-000-CI), 1% Penicillin/Streptomycin (Thermo Fisher, #15140163).

Growth Medium 1S (BPS Bioscience # 78221):

Thaw Medium 1 (BPS Bioscience # 60187), 200 µg/ml of Hygromycin B (Thermo Fisher, #10687010) and 5 µg/ml Blasticidin (InvivoGen, #ant-bl-1). to ensure recombinant expression.

Recommended Culture Conditions

1. It is recommended to quickly thaw the frozen cells from liquid nitrogen in a 37°C water-bath, and then transfer the entire contents of the vial to a tube containing 10 ml of Thaw Medium 1 (no Hygromycin or Blasticidin).
2. Then spin the cells down, remove the supernatant, and resuspend the cells in 5 ml of pre-warmed Thaw Medium 1 (no Hygromycin or Blasticidin).
3. Transfer the resuspended cells to a T25 flask and incubate at 37°C in a 5% CO₂ incubator. After 24 hours of culture, add an additional 3-4 ml of Thaw Medium 1 (no Hygromycin or Blasticidin).
4. At first passage, switch to Growth Medium 1S (contains Hygromycin and Blasticidin)

Subculture:

1. When cells have reached 90% confluency, remove the growth medium and wash twice with PBS (without Magnesium or Calcium).
2. Add 2-3 ml of 0.25% Trypsin/EDTA to the cells and incubate for 2-3 minutes at 37°C.
3. After confirming cell detachment by light microscopy, add 10 mL pre-warmed Growth Medium 1S and gently pipette up and down to dissociate cell clumps.
4. Transfer cells to a 15 ml conical tube and centrifuge at 200 x g for 5 minutes.
5. Remove the medium and resuspend cells in 10 ml pre-warmed Growth Medium 1S.
6. Dispense 2 ml of the cell suspension into a new T75 flask containing pre-warmed 18 ml Growth Medium 1S (a subcultivation ratio of 1:2 to 1:10 is recommended).
7. Incubate cells in a humidified 37°C incubator with 5% CO₂.

Cryopreservation:

1. When cells have reached 90% confluency, use trypsin to remove cells from plate as described above, spin cells and remove medium from the pellet.
2. Resuspend the cells in freezing medium (10% DMSO in FBS).
3. Freeze cells using a reduced rate freezing box (-0.5°C to -1°C per minute) down to -80°C, then transfer cells to liquid nitrogen for long term storage.



Cells have been demonstrated to be stable for at least 15 passages; BPS recommends preparing frozen stocks, so cells are not used beyond passage 20.


Validation Data

Figure 1. Induction of PD-1 in CRISPRa (SAM) HeLa cells.

CRISPRa (SAM) HeLa cells were transduced with sgRNA-MS2 lentivirus targeting PD-1 (BPS Bioscience, #78190) to induce PD-1 expression. Cells were stained 72 hours post-electroporation (with no selection) with PE-labeled anti-PD-1 antibody (BioLegend, #637309) and analyzed by flow cytometry. Parental CRISPRa (SAM) HeLa cells are shown in blue, and the transfected CRISPRa (SAM) HeLa cells are shown in green.

Vector and Sequence

dCas9 (nuclease deficient *Streptococcus pyogenes* Cas9, in blue) fused with a linker (black) and VP64 (red):

DKKYSIGLAIGTNSVGVAVITDEYKVPKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRNRCICYLQEIFSNE
 MAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHELAYPTIYHLRKKLV DSTDKADLRLLIYALAHMIKFRGHFLIEGDLNP
 DNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRENLIAQLPGEKKNLFGNLIASLGLTPNFKSNFDLAEDAKL
 QLSKDTYDDDLNLLAQIGDQYADFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPKEYKEIFF
 DQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREKI
 EKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVDKGASQAQSFIERMTNFDKNLPNEKVLPHKSHLLYEYFTVYNELTKV
 KYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLKIIKDKDFLDNEENEDIL
 EDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFKSDGFANRNFQMQLIHDDSLT
 FKEDIQKAQVSGQGDLSHEHIANLAGSPAIAKKGILQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEEGI
 KELGSQILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLRSDKARGKSDNVPSEE
 VVKMKNYWRQLLNAKLITQRKFDNLTKAERGGSELKAGFIKQQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS
 KLVSDFRKDFQFYKVINNYHHAHDAYLNAVVGTAIIKYPKLESEFVYGDYKVDVRKMIKAKSEQEIGKATAKYFFYSNIMNFFK
 TEITLANGEIRKRLIETNGETGEIVWDKGRDFATVRKVL SMPQVNIKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKYYGGF
 DSPTVAYSVLVAKVEKGSKKLSVKELGITIMERSSEFKNPIDFLEAKGYKEVKDLIIPKYSLELENGRKRMLASAGELQKG
 NELALPSKYVNFYLAHYEKLKGSPEDEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL SAYNKHRDKPIREQAENIIHL
 FTLTNLGAPAAFYFDTTIDRKRYTSTKEVL DATLIHQ SITGLYETRIDLSQLGGDSAGGGGSGGGGSGGGGSGPKKKR KVAAGS
 GRADALDDFDLMLGSDALDDFDLMLGSDALDDFDLMLGSDALDDFDLML

MS2 (in blue) fused with a linker (black), P65 (red), and HSF1 (green):

ASNFTQFVLVDNNGGTGDVTVAPSNFANGVAEWISSNSRSQAYKVTCSVRQSSAQKRKYTIKVEVPKVATQTVGGVELPVAAWR
 SYLNMELTIPIFATNSDCELIVKAMQGLLKDGNPIPSAIAANSIY SAGGGGSGGGGSGGGGSGPKKKR KVAAGSPSGQISNQA
 LALAPSSAPVLAQTMVPSSAMVPLAQPAPAPVLTGPPQSLSAPVPKSTQAGEGTLSEALLHLQFDADEDLGALLGNSTDPGVF
 TDLASVDNSEFQQLLNQGVSMHSTAEPMLMEYEAITRLVTGSQRPPDAPTPLGTSGLPNGLSGDEDFSSIA DMDFSALLSQI
 SSSGQGGGSGFSVDTSALLDLFSPSVTPDMSLPDLSSLASIQELLSPQEP RPPEAENS SPDSGKQLVHYTAQPLFLDPGSVD
 TGSNDLPVLFELGEGSYFSEGDGFAEDPTISLLTGSEPPKAKDPTVS

<i>Products</i>	<i>Catalog #</i>	<i>Size</i>
CRISPRa (SAM) HepG2 Cell Line	78194	2 vials
CRISPRa (SAM) HEK293 Cell Line	78192	2 vials
CRISPRa (SAM) Jurkat Cell Line	78080	2 vials
PD-1 sgRNA-MS2 Lentivirus (Integrating)	78190	2 vials
PD-1 sgRNA-MS2 for CRISPRa (Plasmid)	78091	5 µg

Notes

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.

Reference

Konermann, S., *et al.* Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. *Nature*. 2015. **517(7536)**: 583-588.